Altimmune (NASDAQ:ALT) Stock Keeps Buy Rating at B. Riley Financial

Key Points

• B. Riley reiterated its Buy rating on Altimmune but lowered its price target from $13 to $11.
• Analyst sentiment remains broadly positive: MarketBeat reports a “Moderate Buy” consensus and a $14 average price target, with eight Buy ratings among ten analysts.
• Altimmune’s quarterly loss of $0.15 per share missed expectations of $0.13, while reported Phase 2b study results for investigational pemvidutide showed improvements in liver-disease measures and weight loss.

Altimmune (NASDAQ:ALT - Get Free Report)'s stock had its "buy" rating reiterated by research analysts at B. Riley Financial in a research report issued on Friday, Benzinga reports. They currently have a $11.00 price objective on the stock, down from their prior price objective of $13.00.

Other analysts have also recently issued reports about the stock. Evercore reiterated an "outperform" rating on shares of Altimmune in a research note on Wednesday, September 23rd. HC Wainwright restated a "buy" rating on shares of Altimmune in a research note on Tuesday, July 28th. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Altimmune in a report on Monday, September 21st. Eight investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $14.00.

Altimmune Stock Up 1.8%

Shares of Altimmune stock opened at $1.64 on Friday. The firm has a market cap of $318.82 million, a price-to-earnings ratio of -2.07 and a beta of 0.16. The company has a debt-to-equity ratio of 0.07, a current ratio of 26.78 and a quick ratio of 26.78. Altimmune has a 52-week low of $1.60 and a 52-week high of $6.44. The stock has a 50-day simple moving average of $2.62 and a 200-day simple moving average of $3.17.

Altimmune (NASDAQ:ALT - Get Free Report) last announced its quarterly earnings results on Thursday, November 12th. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.02). On average, equities research analysts expect that Altimmune will post -0.58 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in ALT. Dimensional Fund Advisors LP lifted its holdings in Altimmune by 268.7% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,045,926 shares of the company's stock worth $3,221,000 after purchasing an additional 762,223 shares during the last quarter. Bank of New York Mellon Corp acquired a new position in Altimmune during the second quarter valued at approximately $2,097,000. Hennion & Walsh Asset Management Inc. grew its holdings in Altimmune by 156.5% during the second quarter. Hennion & Walsh Asset Management Inc. now owns 518,198 shares of the company's stock valued at $1,575,000 after purchasing an additional 316,209 shares during the last quarter. Bank of America Corp DE grew its holdings in Altimmune by 48.6% during the first quarter. Bank of America Corp DE now owns 570,203 shares of the company's stock valued at $1,756,000 after purchasing an additional 186,420 shares during the last quarter. Finally, Squarepoint Ops LLC raised its position in shares of Altimmune by 1,016.5% in the second quarter. Squarepoint Ops LLC now owns 202,380 shares of the company's stock valued at $615,000 after purchasing an additional 184,254 shares during the period. Institutional investors and hedge funds own 78.05% of the company's stock.

Key Stories Impacting Altimmune

Investors following ALT have been watching these stories:

• Positive Sentiment: Results published from the 48-week Phase 2b IMPACT study showed significant improvements versus placebo across measures of liver fat, inflammation and fibrosis, alongside weight loss and generally favorable tolerability. The findings support development of pemvidutide for MASH, though the drug remains investigational. Altimmune announces IMPACT Phase 2b 48-week data
• Positive Sentiment: Altimmune reported $480 million in cash, cash equivalents and investments as of September 30. A report said the balance is expected to fund operations through 2029, easing—but not eliminating—near-term financing concerns as key trials advance. Altimmune outlines cash runway and trial milestones
• Negative Sentiment: Altimmune reported a Q3 loss of $0.15 per share, missing the $0.13 loss expected by analysts. Higher R&D spending weighed on results, and continued investment in clinical programs leaves the company dependent on its cash runway and future trial success. ALT Q3 earnings miss, higher costs and funding concerns

About Altimmune

Altimmune, Inc. is a clinical-stage biopharmaceutical company developing peptide-based treatments for obesity and liver diseases. The company is headquartered in Gaithersburg, Maryland. Its lead candidate, pemvidutide, is an investigational medicine that activates GLP-1 and glucagon receptors. Altimmune has studied the drug for obesity and metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease. Altimmune's work focuses on advancing treatments through clinical development; pemvidutide is not an approved medicine.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.